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Background: Normotension has been hold to be the goal of hemodialysis. It remains obscure which cardiovascular
parameter determines the prognosis in these normotensive hemodialysis patients.
Methods: We prospectively enrolled 145 hemodialysis patients, who had attained normotension without
anti-hypertensive medications, and followed them for 72.6 ± 28.5 months. Important cardiovascular parameters
were obtained at enrollment. Predictors for all-cause and cardiovascular mortalities were identified with the Cox
model.
Results: There were 45 (18 cardiovascular/27 non-cardiovascular) deaths occurred during follow-up. Age, diabetes,
left ventricular mass index (LVMI), left ventricular ejection fraction (LVEF), carotid intima-media thickness (CIMT), and
aortic pulse wave velocity (PWV) were significant predictors for all-cause and cardiovascular mortalities. After
adjustment for age and diabetes, only LVEF was significantly associated with all-cause mortality. LVEF was
significantly associated with cardiovascular mortality. LVEF remained as a significant independent predictor of
cardiovascular death after adjusting for age, diabetes, LVMI, CIMT, or PWV, respectively.
Conclusion: LVEF is the independent predictor for all-cause and cardiovascular mortalities in the normotensive
hemodialysis patients.
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There is a globally rising prevalence of end stage renal dis-
ease (ESRD) patients receiving regular hemodialysis. Despite
advances in dialysis facilities and techniques, the mortality
remains high [1]. Hypertension and hemodynamic overload
are widely accepted as the main culprits of the cardiovascular
structural and functional alterations and the cardiovascular
disease, the leading cause of death in these patients [2].
Under hypertension and hemodynamic overload, the cardiac
factors, including left ventricular hypertrophy [3] and left
ventricular dysfunction, [4] have been proposed as the major
cardiac determinants of cardiovascular mortality in the
hemodialysis patients. In addition, arterial factors, including
arterial stiffness, [5] arterial wave reflections, [6] carotid
intima-media thickness (CIMT), [7] and carotid incremental* Correspondence: chench@vghtpe.gov.tw
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reproduction in any medium, provided the orelastic modulus (Einc) [8] have also been recognized as pre-
dictors of cardiovascular outcomes.
Lowering blood pressure (BP) has been widely accepted
to reduce all-cause and cardiovascular mortalities in
patients on dialysis [9]. Most investigators agree that
optimization of fluid status is the initial intervention for
most hypertensive hemodialysis patients. Patients are
instructed to lead a disciplined life with decreasing salt in-
take, maintaining inter-dialytic weight gain within narrow
ranges, while simultaneously keeping adequate calorie in-
take. Data from the Tassin experience [10] and the DRIP
trial [11] suggest that reducing dry weight does improve
BP in a significant number of patients. However, the con-
undrum is that what cardiac or arterial factors govern
mortality when the hemodialysis patients overcome all the
obstacles to attain normotension or dry weight?
In this study, we enrolled hemodialysis patients who had
already attained dry weight, i.e., the body weight at the
end of dialysis at which the patient could remain normo-
tensive until the next dialysis session without the need forThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[10]. All patients received baseline comprehensive cardiac
and arterial structure and function assessments. We aimed
to investigate the cardiovascular determinants of all-cause
and cardiovascular mortalities, and the potential thera-
peutic targets in this unique population.
Methods
Study Patients
The dialysis population consisted of 812 patients treated
at our institution, a nearby community hospital and three
dialysis centers during the period of January 1998 through
December 2002. Patients were considered eligible for in-
clusion when (1) they had been on maintenance
hemodialysis for at least 3 months, and (2) their systolic
blood pressure (SBP) was below 140 mmHg and diastolic
blood pressure (DBP) below 90 mmHg without necessity
of anti-hypertensive medications for at least 90% of 25
consecutive pre-dialysis measurements. There were 620
patients excluded due to hypertension, 38 patients due to
acute diseases and 9 patients due to refusal.
We consecutively enrolled 145 hemodialysis patients
(79 men, 66 women) with a mean age of 55.0 ±
15.0 years. Sixteen patients (11%) were diabetics. Each
subject provided written informed consent, which was
approved by our institutional review board of Taipei
Veterans General Hospital. All participants received a
comprehensive cardiovascular examination and blood
tests on the mid-week non-dialysis day [8].
Hemodialysis procedures
The patients received 4-hour dialysis session thrice-
weekly using 1.6 m2 surface area dialyzers with
bicarbonate-based dialysate (Na+ 140 meq/liter, HCO3
-
39 meq/liter, K+ 2.0 meq/liter, Ca2+ 3.0 meq/liter and
Mg2+ 1.0 meq/liter). In addition to baseline echocardio-
graphic and vascular examinations, they were assessed
via meticulous physical examinations and chest X-ray
and/or echocardiography for adjustment of fluid status
during the follow-up period. Dry weight was defined as
that proposed by Charra et al. [10]. If symptoms and
signs of fluid overload were noted, the exceeded volume
was ultrafiltrated during the dialysis session or via add-
itional sessions. All patients received subcutaneous re-
combinant erythropoietin at a mean dosage of 20,000U
per month to keep their levels of hematocrit up to 30%
according to our National Health Insurance guideline.
Arterial factors
Arterial structure and function were assessed using
ultrasound (SONOS 5500, Philips, Andover, MA, USA)
and arterial tonometry. Supine brachial SBP and DBP
were the average of 4 measurements with an oscillo-
metric device. Pulse pressure (PP) was the differencebetween SBP and DBP. Mean blood pressure (MBP) was
DBP + 1/3 PP.
The measured arterial structural parameter was CIMT
[12]. The arterial functional parameters included aortic pulse
wave velocity (PWV), carotid augmentation index, and
carotid Einc, which were acquired as previously reported [13].
The increased CIMT was defined as CIMT> 0.9 mm and
the increased aortic PWV as PWV> 12 m/s [14].
Cardiac factors
Left ventricular mass and ejection fraction were calculated
from M-mode measurements according to the recommen-
dation of the American Association of Echocardiography
[15]. Left ventricular mass index (LVMI) was left ventricular
mass divided by height2.7 [16]. LVH was defined as LVMI
>50 g/height2.7 for male and >47 g/height2.7 for female.
Supine BP immediately before each dialysis session
was measured using an oscillometric BP monitor. Values
from 25 consecutive dialysis sessions before the cardio-
vascular examination were averaged as pre-dialysis BP.
Uremia related modulators and laboratory evaluation
The clinical biochemistry data was obtained by the
averages of two-month data preceding patients’ entry
into this study. The adequacy of hemodialysis dosage
was indexed by the formulae Kt/V.
Hemoglobin and hematocrit were measured by CELL-
DYNE 1400 (Abbot Laboratories, Abbott park, IL, U.S.A.).
Follow-up
The date and causes of death for the deceased patients
were collected by both telephone contact and review of
hospital charts and death certificates coded according to
the International Classification of Disease, Ninth Revi-
sion (ICD-9). The ICD-9 codes used for cardiovascular
death were 390–459.
Statistical analysis
Data were expressed as mean ± SD for continuous vari-
ables and as proportions for categorical variables.
Between-group comparisons were performed by one-
way ANOVA with Duncan post-hoc test for continuous
variables and by Chi-square test for categorical variables.
Predictors for all-cause and cardiovascular mortalities
were identified with the Cox proportional hazard regres-
sion. Survival curves were plotted using the Kaplan-
Meier method and assessed using the log-rank test.
Values of P <0.05 was considered as statistically signifi-
cant. All statistic procedures were carried out using
SPSS, version 17.0.
Results
The characteristics of the study patients are shown in
Table 1. The previous cardiovascular diseases including 3
Table 1 Baseline characteristics of study patients
Variables Survivors (n = 100) Non-cardiovascular death (n = 27) Cardiovascular death (n = 18)
Age (year) 48.8 ± 13.0* 67.3 ± 13.7 69.1 ± 8.3
Male gender,% 53% 61% 55%
Weight (kg) 59.3 ± 10.5 60.4 ± 8.2 59.7 ± 9.7
Height (cm) 161 ± 9 161 ± 7 158 ± 9
BMI (kg/m2) 22.8 ± 3.3 23.3 ± 3.0 23.7 ± 2.8
Diabetes (%) 4%* 18%# 41%
History of cardiovascular disease (%) 6%* 29% 31%
Hypertension history (%) 17.0 22.2 27.1
Previous hypertension duration (years) 13.3 ± 4.7 12.6 ± 3.2 13.8 ± 5.0
Medications
Vitamin D receptor agonists (%) 15.1 22.0 18
Lipid lowering agents (%) 28.3 22.2 20
Dialysis duration (days) 2178 ± 2006 978 ± 1018 1508 ± 1124
Systolic BP (mmHg) 114 ± 17 107 ± 19 116 ± 15
Diastolic BP (mmHg) 66 ± 12 61 ± 10 68 ± 10
Pulse BP (mmHg) 47 ± 9 46 ± 13 49 ± 11
Systolic BPavg (mmHg) 126 ± 19 119 ± 19 131 ± 18
Diastolic BPavg (mmHg) 75 ± 10 70 ± 9 76 ± 8
Pulse BPavg (mmHg) 51 ± 10 49 ± 13# 55 ± 13
Hematocrit (%) 31.0 ± 4.2* 30.0 ± 2.9 29.3 ± 2.7
Hemoglobin (g/L) 103 ± 15 100 ± 11 100 ± 8
Kt/V 1.56 ± 0.31 1.50 ± 0.18 1.44 ± 0.22
LVMI (g/height2.7) 50.3 ± 14.1* 51.6 ± 15.3# 72.1 ±31.0
LV EF (%) 71 ± 8* 72 ± 13# 62 ±17
Carotid IMT (μm) 774 ± 166* 875 ± 146# 1015 ± 249
Carotid Augmentation Index (%) 13.8 ± 20.3 14.5 ± 14.5 19.3 ± 20.6
Carotid Einc (kPa*10
3) 0.39 ± 0.20 0.41 ± 0.26 0.45 ± 0.17
PWV (m/s) 8.3 ± 3.0* 10.3 ± 4.2# 12.8 ± 2.2
*: P value <0.05 for comparison between survivors and cardiovascular deaths.
#: P value < 0.05 for comparison between non-cardiovascular and cardiovascular deaths. BMI = body mass index; BP = blood pressure; BPavg = pre-dialysis blood
pressure averaged from 25 consecutive hemodialysis sessions; Einc = incremental elastic modulus; IMT = intima-media thickness; LV EF = left ventricular ejection
fraction; LVMI = left ventricular mass index; PWV = pulse wave velocity.
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cardiovascular diseases. There were no significant differ-
ence of the types of previous cardiovascular disease among
the survivors, non-cardiovascular mortality, and cardio-
vascular mortality. During a mean follow-up of 72.6 ±
28.5 months, no patients received renal transplant or lost
to follow up. There were 18 cardiovascular and 27 non-
cardiovascular deaths. The mean annual all-cause mortal-
ity was 5.1% and cardiovascular mortality was 2.1%. There
were 9 patients with abnormal LVEF, 77 patients with
LVH, 39 patients with increased thickness of CIMT, and
21 patients with increased PWV. Patients died from car-
diovascular causes were older than the survivors and were
more likely to have type 2 diabetes mellitus. They also had
significantly higher LVMI, lower LVEF, greater CIMT, andfaster PWV. In comparison with those who died from
non-cardiovascular causes, patients died from cardiovas-
cular causes also had significantly higher LVMI, lower
LVEF, greater CIMT, and faster PWV.
Univariate analysis of significant predictors for all-cause
mortality included age, diabetes mellitus, pre-dialysis DBP,
history of cardiovascular disease, hematocrit, LVMI, LVEF,
CIMT, and PWV (Table 2). Regarding cardiovascular
mortality, age, diabetes mellitus, history of cardiovascular
disease, LVMI, LVEF, CIMT, and PWV were significant
predictors (Table 2).
Among the four key cardiac (LVMI, LVEF) and arterial
factors (CIMT, PWV) that could have prognostic impacts,
only CIMT (r = 0.46, P <0.001) and PWV (r = 0.59,
P <0.001) were significantly correlated with age.
Table 2 Hazard ratios of all-cause and cardiovascular mortality based on univariate Cox regression models
Variable All-cause mortality Cardiovascular mortality
Hazard Ratio (95% CI) P value Hazard Ratio (95% CI) P value
Age (year) 1.08 (1.05-1.11) <0.001 1.09 (1.04-1.14) <0.001
Sex (men = 1, female = 0) 1.15 (0.64-2.03) 0.6 0.91 (0.35-2.38) 0.9
BMI (kg/m2) 1.02 (0.94-1.11) 0.7 1.04 (0.91-1.20) 0.5
Diabetes (yes =1, no = 0) 4.47 (2.28-8.76) <0.001 7.80 (2.91-20.92) <0.001
History of cardiovascular disease (yes = 1, no = 0) 2.85 (1.47-5.45) 0.002 3.10 (1.08-8.93) 0.04
Dialysis duration (days) 1.0 (0.99-1.00) 0.4 1.0 (1.00-1.00) 0.4
Systolic BP (mmHg) 0.99 (0.98-1.01) 0.9 1.01 (0.98-1.04) 0.4
Diastolic BP (mmHg) 0.98 (0.96-1.004) 0.9 1.02 (0.97-1.06) 0.7
Pulse BP (mmHg) 1.00 (0.97-1.03) 0.9 1.03 (0.99-1.08) 0.5
Systolic BPavg (mmHg) 0.99 (0.98-1.006) 0.2 1.01 (0.99-1.04) 0.3
Diastolic BPavg (mmHg) 0.97 (0.94-0.99) 0.03 1.00 (0.93-1.07) 0.9
Pulse BPavg (mmHg) 1.00 (0.98-1.02) 0.7 1.03 (0.99-1.06) 0.2
Hematocrit (%) 0.91 (0.84-0.99) 0.04 0.91 (0.78-1.04) 0.2
Kt/V 0.43 (0.16-1.15) 0.09 0.52 (0.11-2.49) 0.4
LVMI (g/height2.7) 1.02 (1.005-1.04) 0.01 1.04 (1.02-1.06) <0.001
LV EF (%) 0.97 (0.947-0.998) 0.03 0.94 (0.91-0.97) <0.001
Aorta dimension (mm) 1.69 (0.73-3.92) 0.2 1.36 (0.34-5.45) 0.7
Carotid IMT(μm) 1.002 (1.001-1.004) 0.02 1.0053 (1.001-1.006) 0.003
Carotid augmentation index (%) 1.00 (0.98-1.02) 0.9 1.01 (0.98-1.04) 0.4
Carotid Einc (kPa *103) 2.45 (0.70-8.56) 0.2 2.61 (0.35-19.34) 0.4
Aortic PWV (m/s) 1.13 (1.06-1.20) <0.001 1.19 (1.09-1.29) <0.001
BMI = body mass index; BP = blood pressure; BPavg = pre-dialysis blood pressure averaged from 25 consecutive hemodialysis sessions; Einc = incremental elastic
modulus; IMT = intima-media thickness; LV EF = left ventricular ejection fraction; LVMI = left ventricular mass index; PWV = pulse wave velocity.
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dependent predictor, when age and diabetes mellitus
were accounted for (Table 3, Model 1). CIMT and PWV
were not significant independent predictors for all-cause
mortality after adjusted for age and diabetes (Tables 3,
Model 2). LVEF remained as a significant predictor when
CIMT was entered into the model (Table 3, Model 3).
LVEF also remained as a significant predictor when aor-
tic PWV was entered into the model (Table 3, Model 4).
For cardiovascular mortality, LVEF was also an inde-




P value Hazard Ratio
(95% CI)
Age (year) 1.07 (1.04-1.10) <0.001 1.07 (1.04-1.11)
Diabetes (yes = 1, no = 0) 1.81 (0.89-3.70) 0.1 1.93 (0.86-4.2)
LVMI (g/height2.7) 1.003 (0.99-1.02) 0.5
LV EF (%) 0.97 (0.95-0.99) 0.015
Carotid IMT (μm) 1.05 (0.87-1.26)
Aortic PWV (m/s) 0.96 (0.87-1.06)variate analysis because of the low number of cardiovas-
cular death. LVEF remained as a significant predictor of
cardiovascular death in analyses adjusting for age, dia-
betes, LVMI, CIMT, or PWV, respectively (Table 4).
In the normotensive hemodialysis patients, LVEF
<50% (median value) predicted cardiovascular mortality
(Figure 1). We compared blood pressure, LVMI, carotid
IMT, carotid augmentation index and PWV between
groups of above and below LVEF 50%. There was no sig-
nificant difference of blood pressure (systolic BP:113 ±
18 mmHg vs. 108 ± 14 mmHg, p = 0.3; diastolic BP:riate Cox regression models
l 2 Model 3 Model 4
P value Hazard Ratio
(95% CI)
P value Hazard Ratio
(95% CI)
P value
<0.001 1.07 (1.04-1.10) <0.001 1.07 (1.05-1.11 <0.001
0.1 1.86 (0.92-3.76) 0.08 2.14 (0.96-4.76) 0.06
0.97 (0.95-0.99) 0.008 0.97 (0.95-0.99) 0.01
0.6 1.07 (0.89-1.29) 0.4
0.5 0.96 (0.88-1.06) 0.4
Table 4 Hazard ratios of cardiovascular mortality based
on restricted multi-variate Cox regression models
LVEF (%)
Adjusted variable Hazard ratio 95% CI P value
Age (year) 0.95 0.92 - 0.98 0.001
Diabetes (yes = 1, no = 0) 0.95 0.92 - 0.98 0.004
LVMI (g/height2.7) 0.96 0.93 - 0.99 0.03
Carotid IMT (μm) 0.94 0.91 - 0.98 0.001
Aortic PWV (m/s) 0.95 0.92 - 0.99 0.006
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47 ± 11 vs. 43 ± 7 mmHg, p = 0.3), carotid IMT (813 ±
178 μm vs. 899 ± 263 μm, p = 0.1 ), carotid augmentation
index (14.7 ± 19.3 m vs. 14.6 ± 17.9 m, p = 0.9) and PWV
(9.0 ± 3.5 m/s vs. 9.9 ± 2.9 m/s, p = 0.4) between groups of
above and below LVEF 50% ; only borderline significant
for LVMI (51 ± 15 gm vs. 72 ± 38, p = 0.09).Discussion
The present study demonstrated that even in hemodialysis
patients who had already attained normotension/dry
weight, reduced LVEF was an independent predictor for
both all-cause and cardiovascular mortalities. Compared
with the general hemodialysis patients, [17] we also con-
firmed that the normotensive hemodialysis patients had a
relatively favorable prognosis.
Reduced LVEF is associated with adverse cardiovascu-
lar events in ESRD patients [18]. It should be noted that
that even mild LV systolic dysfunction may significantly
deteriorate the prognosis in the general hemodialysis
patients [19]. In a 7 years followed up of 1,254 incident
hemodialysis patients with 71.9% being hypertensive,
reduced LVEF on starting hemodialysis was a strongFollow-up (months)


















LVEF  50% 
LVEF < 50%
P < 0.001
Figure 1 Cardiovascular (CV) survival curves for left ventricular
ejection fraction (LVEF) (Panel A, log rank test P < 0.001) and
left ventricular mass index (LVMI) (Panel B, log rank test
P = 0.03).independent predictor for all-cause and cardiovascular
deaths [19].
High BP has well been recognized as a major determin-
ant of deranged cardiovascular structure and function and
an independent predictor of cardiovascular risk in the gen-
eral population and in patients with ESRD [13]. Therefore,
lowering BP by adjusting dry-weight and adding necessary
antihypertensive drugs has been proposed to diminish the
cardiovascular mal-adaptation. In a previous cross-
sectional study, we have observed favorable cardiovascular
structural and functional remodeling in the normotensive
hemodialysis patients when compared with the hyperten-
sive hemodialysis counterparts [12]. However, attaining
normotension could not fully reverse the cardiovascular
structure and function to normal [12]. These patients still
have increased LVMI due to persistent flow overload and
subclinical left ventricular dysfunction. The present pro-
spective study further highlights the importance of the
persistent left ventricular structural and functional para-
meters in determining prognosis.
We have shown previously that volume status was
closely related to the structure and function of the large
artery in hemodialysis patients [20]. Therefore, the arter-
ial structure (aortic diameter and CIMT) and function
(PWV, carotid augmentation index, and carotid Einc)
could be modified by probing dry weight to reduce BP.
We reasoned that the arterial factors might have been
improved substantially in normotensive state, and thus
might become less important in predicting outcomes.
The present study supports the reasoning and also im-
plies that targeted interventions towards cardiac struc-
ture and function may further improve clinical outcomes
in the normotensive hemodialysis patients.
The uremic milieu other than the pressure/volume over-
load, such as anemia, deranged calcium-phosphate
homeostasis, secondary hyperparathyroidism, sympathetic
overactivity, increased oxidative stress, chronic inflamma-
tion and accumulated uremic toxins, etc. already exist in
the predialysis stages. All these factors intricately partici-
pate in the pathogenesis of cardiovascular derangements,
[21] and the cardiovascular changes are already quite pro-
nounced by the time patients commence hemodialysis.
Therapy targeted toward single factor usually fails to im-
prove hemodialysis prognosis. For example, a 12-month
treatment with ramipril did not cause significant regres-
sion of left ventricular hypertrophy in normotensive
hemodialysis patients [22]. Therefore, a multi-disciplined
interventional strategy may be required to offer optimal
cardiac and overall outcomes.
Notwithstanding better BP control, demographic para-
meters such as age and diabetes mellitus still played piv-
otal roles in affecting the prognosis of our normotensive
hemodialysis patients. Actually, patients’ age per se exerts
impacts on cardiovascular structure and function [23].
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exerted deleterious effects on clinical outcomes in our
normotensive hemodialysis patients. Diabetes is a well
known risk factor for ischemic heart disease, reduced car-
diac function, and cardiac events in uremic patients [24].
Given the increasing prevalence of elderly and diabetic
dialysis patients, [25] individualized treatment plans
designed for patients with different demographic features
may be needed, even if they have already achieved
normotension by hemodialysis.
The present study is limited by the small number of
enrolled patients as relatively few HD patients can re-
main normotensive without taking antihypertensives.
Further multicenter studies with longer prospective
follow-up for more events would facilitate detailed
multivariate analysis by taking into account more cardio-
vascular risk factors as the nutrition status, inflammatory
markers, [26] and calcium-phosphate homeostasis, etc.
Conclusions
In conclusion, the normotensive hemodialysis patients
usually have relatively good all-cause and cardiovascular
mortality outcomes. LVEF appears to be a major pre-
dictor for all-cause and cardiovascular mortalities in this
unique population. Future studies are required to inves-
tigate whether targeted interventions to improve cardiac
systolic function may further improve clinical outcomes
in these patients.
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